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A B S T R A C T
Parkinson’s disease (PD) is characterised pathologically by degeneration of the dopaminergic (DA) neurones of
the substantia nigra pars compacta (SNpc) and the presence of α-synuclein containing Lewy body inclusions.
Trichloroethylene (TCE) has been suggested as a potential environmental chemical that may contribute to the
development of PD, via conversion to the neurotoxin, 1-Trichloromethyl-1,2,3,4-tetrahydro-β-carboline (TaClo).
We investigated the effect of an 8 week exposure to TCE or TaClo on wild type and, as an experimental model of
PD, A30P mutant α-synuclein overexpressing mice using a combination of behaviour and pathology. TCE or
TaClo exposure caused significant DA neuronal loss within the SNpc in both wild type and transgenic mice. Cell
numbers were lower in A30P animals than wild type, however, no additive effect of TCE or TaClo exposure and
A30P overexpression was found. TCE or TaClo did not appear to lead to acceleration of motor or cognitive
deficits in either wild type or A30P mutant mice, potentially because of the modest reductions of DA neuronal
number in the SNpc. Our results do however suggest that TCE exposure could be a possible factor in development
of PD like changes following exposure.
1. Introduction
Parkinson’s disease (PD) is the leading cause of neurodegenerative
motor impairment and is characterised by progressive loss of the do-
paminergic (DA) neurones of the substantia nigra pars compacta
(SNpc). Clinically, PD manifests as a triad of bradykinesia, rigidity and
resting tremor that becomes apparent when 50–70% of the DA neu-
rones of the SNpc are lost [1]. The exact mechanism by which SNpc cell
death occurs is poorly understood, but is thought to involve both en-
vironmental and genetic factors. One current suggestion is that in ge-
netically predisposed individuals, exposure to an unidentified en-
vironmental chemical(s) leads to cell death in the enteric nervous
system and spread of alpha-synuclein pathology to the central nervous
system and the SNpc [2]. Trichloroethylene (TCE), a commonly used
industrial solvent, is one potential environmental chemical that may
contribute to the development of PD and similar forms of parkinsonism.
TCE can be continually present in the environment in areas of previous
TCE use and workers can be exposed to levels of 100 ppm in the air [3].
There have been links between chronic exposure to TCE and parkin-
sonian symptoms [4–7], and treatment of rats or mice with TCE causes
SNpc DA neurone degeneration [8,9]. TCE can be converted, via
chloral, to a potential neurotoxin, 1-trichloromethyl-1,2,3,4-tetra-
hydro-β-carboline (TaClo) in man [10], which can cross the blood brain
barrier [11]. TaClo can cause up to 50% cell death in primary DA
neurones cultures [12], as well as in vivo exposure, leading to a re-
duction in DA metabolism [13] and altered locomotor activity [14–16].
How TCE or TaClo might lead to parkinsonism is unclear since both
potentially can cause peripheral neuronal damage and consequent
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pathological spread, or may directly affect SNpc neuronal viability.
Alpha-synuclein, the major constituent of Lewy bodies in PD, has
been shown to be important in the development of experimental PD
[17] and mutations in the α-synuclein gene cause familial PD [18]. One
such mutation (A30P) [19], has been shown to reduce α-synuclein
degradation [22,23], potentially leading to increased cellular α-synu-
clein levels. The A30P mutation also causes increased oligomerisation
and fibrillization into toxic aggregates [20]. C57BL/6 mice expressing
human A30P α-synuclein develop symptoms that replicate aspects of
PD with abnormal age dependent α-synuclein accumulation in the
brainstem, thalamus, and cortex, along with abnormal locomotor be-
haviour and are a useful model of PD [21].
While there is evidence for both genetic and environmental risk
factors in development of PD, for most cases there is likely a complex
interplay between genetic and environmental influences in the causa-
tion of PD. We therefore tested the hypothesis that exposure to TCE
might contribute to PD development, and whether TaClo might achieve
similar effects. We therefore assessed the effects of TCE and TaClo ex-
posure in A30P mutant α-synuclein mice as a model of PD and in wild
type mice.
2. Materials & methods
All experiments were carried out according to the UK Animals
(Scientific Procedures) Act of 1986, with UK Home Office Guidance and
the European Community Council Directive of 24 November 1986 (86/
609/EEC).
A30P mutant human α-synuclein overexpressing mice develop a
motor defect at 14–16 months of age [21–23]. To determine if TCE or
TaClo exposure caused an acceleration of any deficits, exposure ex-
periments were conducted on younger mice. Fifteen week old male and
female wild type C57BL/6 mice (Charles River UK, Margate) and A30P
mutant human α-synuclein overexpressing C57BL/6 mice were housed
in clean holding rooms. Mice were kept in groups of up to 6 in solid
bottomed, saw dust filled filter top individually ventilated cages with
environmental enrichment available throughout the study period. The
rooms were illuminated by fluorescent lights set to give a 12 h light-
dark cycle (on 07.00, off 19.00). Animals were fed a diet of RM03 ro-
dent diet (Special Diet Services, Edinburgh, UK) ad libitum and had free
access to mains tap water.
Ten wild type and ten A30P overexpressing mice per treatment
group (five male and five female) were intraperitoneally injected twice
weekly with 10ml/kg of either olive oil as vehicle, 1000mg/kg TCE in
olive oil or 2mg/kg TaClo in 0.1% DMSO in 0.9% NaCl for eight weeks.
Doses were established using prior dose ranging studies in wild type
mice as being suitable and showing no acute short term effects on body
weight and feeding. Each mouse was weighed prior to every injection
during the dosing period and then weekly for the duration of the study.
The effects of chemical administration on weight loss were analysed by
ANOVA followed by Bonferroni test with significance set at p < 0.05.
2.1. Behavioural testing
Pre-dose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36 and 40 weeks after
initial treatment, all animals were subjected to rotarod, grip-strength
and pole tests. For the Barnes maze, spatial learning was tested in all
animals at 41 weeks post initial dose and spatial memory in week 41
(short-term) and 42 (long-term). The effects of chemical exposure on
behaviour were analysed by ANOVA followed by Bonferroni test with
genotype, sex, and time as cofactors.
Motor function was assessed by an accelerating rotarod (IITC Life
Sciences WPI, Hertfordshire, UK) [24]. Animals were trained at a
constant speed of 3 rpm prior to testing. On test days, animals were
tested in 3 trials with 15min between trials. For each trial, animals
were placed on the rod at a speed of 3 rpm and the rod steadily ac-
celerated to 30 rpm over 300 s and the fall latency for each animal
recorded. If they did not fall, a latency of 300 s was recorded.
Fore paw grip strength was measured using a grip test device
(BIOSEB, Vitrolles, France)[25]. Each mouse was allowed to grip a wire
mesh with its forepaws and was gently pulled back by the tail until its
grip was broken. The average of three measurements was taken for each
animal.
Fine motor function was assessed using the pole test [26]. Animals
were trained to grip, face up, on the top of an 8mm diameter, 55 cm
high polypropylene threaded pole (Shop4fasteners.co.uk, Sheffield,
UK), within the home cage and had to turn around and climb down on 3
separate occasions prior to testing. On test days, animals were timed in
the activity for 3 trials separated by at least 15min. Time to turn, time
to descend, total time to complete the trial and number of falls over 3
trials were recorded. If the animal did not complete the task or fell, a
time of 30 s was recorded.
Spatial learning and memory were assessed using a Barnes maze
[27] in weeks 40 and 41. The paradigm consisted of a 96 cm diameter
grey plastic disk maze with 20 equally spaced holes (5 cm diameter),
2 cm from the maze edge at 70 cm above the floor. One hole, the
‘target’, had access to a small dark escape chamber located under the
maze, with no visual discrimination between this and other holes. A
barrier surrounded the maze with distinct visual cues (A4 size filled
square, circle, triangle and cross) attached at the cardinal points to give
the animals spatial reference points and the room, including the ex-
perimenter, were kept in constant configuration throughout the dura-
tion of the experimental protocol. All experimental procedures were
recorded using Panasonic SDR-S26 video camera for scoring.
On Day 0 (adaption phase) mice were placed in a 10.5 cm diameter
chamber in the centre of the maze (start chamber) for 10 s before being
released. The mouse was then gently guided to the target hole and
encouraged to enter the escape chamber. Once in the escape chamber,
the entrance was covered and the mouse was left for 2min then re-
turned to the home cage. Four times per day on days 1–4 with a 15min
inter-trial interval mice were placed in the start chamber for 10 s and
then released into the maze and they were allowed to explore for 3min
to assess spatial acquisition. During the exploration period, primary
errors (the amount of times incorrect holes were explored before
finding the target – nose pokes), total errors (the amount of times in-
correct holes explored before entering the target hole escape chamber),
primary latency (the amount of time taken to find target hole) and total
latency (the amount of time taken to enter target hole) were recorded.
The trial ended when the mouse entered the escape chamber or 180 s
had elapsed if the escape chamber was not entered, and the mouse was
gently encouraged to enter the chamber. Once in the escape chamber,
the entrance was covered and the mouse was left for 1min then re-
turned to the home cage. Between trials the maze was cleaned with
70% ethanol and the maze rotated 90° to remove olfactory cues. The
effects of chemical exposure on spatial memory were analysed by Two-
way Repeated Measures ANOVA followed by Bonferroni test with sig-
nificance at p < 0.05.
On Day 5, 24 h following the last training day, and on Day 12 (probe
trials), a trial was conducted to assess short and long term retention
respectively. The escape chamber was removed and mice were placed
in the start chamber as previously and then released into the maze to
explore for 90 s. Number of pokes (errors) in each numbered hole was
recorded. The effects of chemical exposure on short and long term
spatial memory were analysed by unpaired t-test for each hole.
Significance was set at p < 0.05.
2.2. Neuronal counting
Animals were terminally anaesthetised in 3% isofluorane (Isoflo®
100% w/w Inhalation Vapour, Abbott Laboratories Ltd, Maidenhead,
UK) in O2 and killed by rapid decapitation at 42 weeks post dose, just
prior to typical onset of motor symptoms. Brains were dissected from
animals, hemisected and fixed by immersion in ice cold 10%
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formaldehyde (Sigma) in phosphate buffered saline. Brain tissue from 6
animals (3 male and 3 female) were randomly selected from each
treatment group and embedded in paraffin wax. Coronal tissue sections
(30 μm) were taken rostral to the SNpc at bregma -2.78mm throughout
the SNpc until caudal to bregma -3.78mm and every 5th section se-
lected for analysis, giving a total of 9 sections per animal. Sections were
stained for DA neurones with anti-tyrosine hydroxylase antibody and
general nuclei stained using Cresyl Violet. Briefly, sections were de-
waxed in xylene (Fisher Scientific) before rehydration in decreasing
ethanol solutions. Antigen retrieval was carried out by boiling in
1.27mM EDTA (Tetrasodium Dihydrate, USB Products, High Wycombe,
UK) pH 8 in a microwave for 10min before allowing to cool for 20min
and then immediately transferring to ddH2O. Sections were quenched
in 0.9% H2O2 in TBS followed by 3 washes in TBS and then blocked in
goat serum in TBS for 30min prior to primary (rabbit polyclonal anti-
body to TH (Abcam) 1:500 in TBS containing blocking goat serum at
4 °C overnight) and secondary incubation (Vectastain Elite ABC Rabbit
IgG kit, Vector Laboratories, Peterborough, UK) 1:200 in blocking
serum in TBS for 30min at room temperature. Sections were washed
then treated with Vectastain ABC reagent for 30min at room tem-
perature, washed and then exposed to 0.25mg/ml 3,3′-
Diaminobenzidine (DAB) in TBS with 0.02% H2O2 for 10min, before
being washed and counterstained with Cresyl Violet in Acetate Buffer
(pH 4.5), dehydrated in ethanol, cleared in xylene and coverslips
mounted with DPX (Fisher Scientific).
Unbiased estimates of the total number of TH positive neurones
were calculated using a Zeiss Imager.Z1 microscope attached to an
AxiocamMR3c camera with StereologerTM Ver 2.1 CP-Version
(Stereology Resource Centre, Chester, Maryland, USA) software. A
frame height of 12 μm ± a guard height of 2 μm were used based on an
average section thickness following shrinkage during processing of
16.56 ± 0.31 μm and there was no significant difference between
thickness in any treatment group (see Supplementary Table 1).
Total number and volume of TH positive neurones were counted at
high (x40) magnification using unbiased multi-level (fraction-based)
estimates throughout the SNpc. Volumes of all TH positive neurones
were estimated using an isotropic uniform randomly assigned nucleator
probe [28]. The coefficient of error (CE) for cell number (num) and
volume (vol) estimates were calculated [29] and CE values< 0.10 were
considered acceptable (see Supplementary Table 1).
Alpha-synuclein immunohistochemistry was used to determine if
Lewy body like alpha-synuclein inclusions were formed in the SNpc
following TCE or TaClo exposure and used anti-phosphorylated alpha-
synuclein antibody (1:100 dilution; Abcam, Ab51253) following an-
tigen retrieval with 0.01M sodium citrate buffer (pH6.0) for 20min.
Antibody binding was detected using HRP conjugated anti-rabbit anti-
body (1:200 dilution; Vector, PK82000) and sections developed using
DAB as previously.
3. Results
Animals in all treatment groups showed no overt signs of toxicity
and showed a similar normal increase in weight over time
(Supplementary Fig. 1).
3.1. Behavioural tests
To assess motor function, an accelerating rotarod was used prior to
and every 4 weeks until 40 weeks after the first dose. No significant
differences between treatment groups and no significant effect of
treatment over time was found in either A30P mutant or wild type
mice, but there was a significant decrease in performance over time
across all groups (Fig. 1). No significant difference was seen at any time
point for any treatment when compared to vehicle.
The pole test showed no significant differences in total trial time
between treatment groups or effect of treatment over time, but there
was a significant increase in total trial time over the test period in all
mice indicating poorer performance with age in both groups (Fig. 2).
No significant differences in number of falls were seen between treat-
ment groups with no significant effect of treatment over time, but a
significant increase in falls was observed in both A30P and wild type
mice over time (Fig. 2B). No significant changes in falls in TCE and
TaClo treated mice were seen in the A30P group (Fig. 2B).
As abnormalities in grip strength have been reported in PD mice
[30] and spinal pathology is seen in A30P mice, grip strength was
tested. There were no significant differences observed in grip strength
between treatment groups, and no significant effect of treatment over
time in any group, although there was a significant difference over time
in both groups indicating decreased grip with age (Supplementary
Fig. 2).
Previous studies have shown that A30P mice show cognitive deficits
[31]. To determine if TCE or TaClo accelerated cognitive changes,
learning and memory were assessed using a Barnes maze. For all
treatment groups and in A30P and wild type mice, there were no sig-
nificant differences between treatment groups or of treatment over
time, but all animals significantly improved at finding and entering the
escape box over the study period (Fig. 3). Memory on Day 5 (short term
memory) and Day 12 (long term memory) showed no significant dif-
ferences in any treatment group and in either A30P or wild type mice
(Supplementary Fig. 3).
3.2. DA cell number
As SNpc DA neurone loss is characteristic of PD [1], DA neurone
number and size were assessed using stereology to accurately estimate
DA neurones. Multivariate analysis of variance (MANOVA) showed a
statistically significant interaction effect between mouse model and
treatment on the cell number, volume and density F(4, 58)= 5.217,
p < 0.001, Wilks' Lambda=0.425. Post hoc univariate analysis on the
outcome variables revealed significant effects of strain and treatment
on cell density F(5, 29)= 7.361, p < 0.003 and number F(5,
29)= 4.236, p=0.043, but not on cell volume F(5, 29)= 0.163,
p=0.850. When comparing TH-positive cell (DA neurone) number
between A30P and wild type mice, A30P animals showed a significantly
lower cell number compared to wild type mice when comparing vehicle
treated animals (p=0.014) (Fig. 4A). In wild type animals, a sig-
nificant decrease in TH-positive cell number in the SNpc was seen in
both TCE and TaClo exposed groups (p < 0.001; Fig. 4A, and
Fig. 1. Effect of TCE and TaClo on A30P α-synuclein and wild type C57BL/
6 Mice on Motor Function Using Rotarod.
Average fall latency (sec) of vehicle (10ml/kg olive oil), TCE (100mg/kg) or
TaClo (2mg/kg), treated wild type or A30P C57BL/6 mice over time, triplicate
trials. Data presented as mean ± SEM (n=8–10). Significant difference over
time (p < 0.05, p < 0.001 respectively), No significant difference between
treatment groups or of treatment over time, Two-Way (treatment, time)
Repeated Measures ANOVA.
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Supplementary Fig. 4), with cells reduced to approximately 50% of
vehicle levels in wild type animals (Fig. 4A). For A30P animals, ex-
posure to TCE (p= 0.012) and TaClo (p=0.002) caused a significant
reduction of TH-positive cell number to approximately 70% of vehicle
treated A30P mice (Fig. 4A). TaClo treated A30P mice showed sig-
nificantly reduced cell TH-positive neurone number when compared to
TaClo treated wild type animals (p=0.049, Fig. 4A). Analysing cell
density in vehicle only animals showed a significant reduction in cell
density in A30P mice compared to wild type mice (p=0.001; Fig. 4B).
Following TCE or TaClo treatment, TH-positive cell density in the SNpc
showed a 50% decrease in TCE and TaClo treated wild type animals
compared to vehicle wild type animals (p < 0.001; Fig. 4B). In A30P
mice, no reduction in density between vehicle and TaClo (p < 0.61) or
in TCE treated A30P mice (p=1.00; Fig. 4B) was observed. Estimated
SNpc volumes were unchanged (see Supplementary Fig. 5). This data
suggests that exposure to both TCE and TaClo leads to a decrease in TH-
positive neurones in the SNpc, but that there is only a small additive
effect of mutant A30P overexpression in combination with these che-
micals. TH-positive neuronal cell body volume was unchanged (Sup-
plementary Fig 6). Use of phosphorylated alpha-synuclein antibody to
detect Lewy body like inclusions failed to detect any changes in SNpc in
vehicle or treated wild type or A30P overexpressing mice (data not
shown).
4. Discussion
During this study, wild-type and A30P mutant overexpressing
C57BL/6 mice from all groups showed normal weight gain throughout
the duration of the study with no significant differences apparent be-
tween treatment groups, suggesting that TCE and TaClo were relatively
well tolerated.
The rotarod test has been previously used to show a decrease in
motor function following acute exposure to MPTP and rotenone [53,
54] and in a rat model of TCE exposure [8]. No significant decrease in
motor function was observed in TCE or TaClo mice compared to vehicle
treated groups in wild type or A30P mutant mice in the current study.
Similarly, we found no difference in motor function using rotorod be-
tween wild type and A30P mice, consistent with previous studies [28].
Since we aimed to show acceleration of pathology by TCE or TaClo by
determining motor behaviour before the normal onset of major motor
symptoms, we can conclude that neither TCE nor TaClo lead to any
marked acceleration of major motor symptoms.
Fine motor control is reduced in the pole test and beam test in the
A30P mouse [32]. Analysis of mice in this study by the pole test found
no difference in fine motor control between vehicle and TCE or TaClo
treated groups in either wild type or A30P overexpressing animals, si-
milar to findings with hanging wire [32]. All treatment groups of both
strains showed a general increase in the time taken to turn and descend
the pole and to complete the task, as well as in the number of falls
recorded. This decrease in fine motor control over time may be due to
habituation as it occurred across all treatment groups and the majority
of previous published uses of the pole test have not typically used it
repeatedly.
There was a significant decrease in grip strength over time in all
treatment groups of both strains, which manifested as a sharp decrease
from pre-dose to 4 weeks, which then levelled off across the rest of the
study period. No significant difference following treatment or between
strains in wild type or A30P animals was seen. Grip strength may not be
a sensitive marker for motor dysfunction since mice that show de-
creased motor function assessed by rotarod have no significant change
in grip strength [33]. The strain of A30P mutant α-synuclein over-
expressing mice used shows spinal cord pathology, with a weakening of
extremities at 17 months [21,23] and defects in fine motor function
[32]. However, no differences in grip strength or gait were seen be-
tween wild type and A30P mutant animals in this study, indicating that
specific motor tests may be required [32]. TCE and TaClo therefore
appear not to cause any marked acceleration of a major motor pheno-
type in A30P animals.
PD has been widely associated with cognitive decline [34]. In ad-
dition, there is a decrease in cognition in A30P mutant α-synuclein
overexpressing mice, as well as α-synucleinopathy in the central nu-
cleus of the amygdala, an area involved in cognitive behaviour in mice
[31]. In this study, no significant differences were found following
treatment in either wild type or A30P mutant animals in any parameter
analysed suggesting that TCE or TaClo have no effect on spatial
learning. However, when comparing wild type and A30P mutant ani-
mals, A30P mutant animals took significantly longer to find the target
hole on the first day of the trial, suggesting a possible learning deficit
when compared to wild type C57BL/6. Spatial memory was unaffected
in TCE or TaClo treated and vehicle groups in short or long term
memory in either strain. This lack of effect of TCE and TaClo on spatial
learning and memory correlates with a study which reported no effect
on learning and memory in TaClo exposed rats using the COGITAT hole
board [35]. Combined with our results, this suggests that TCE/TaClo do
not contribute to the cognitive deficits seen in PD in toxin-based rodent
models.
Fig. 2. Effect of TCE and TaClo on wild type and A30P α-synuclein C57BL/
6 Mice as Assessed by the Pole Test.
Average (A) total time, and (B) Number of falls per trial of vehicle (10ml/kg
olive oil), TCE (100mg/kg) or TaClo (2mg/kg), treated wild type or A30P α-
synuclein overexpressing C57BL/6 mice over time, triplicate trials. Data pre-
sented as mean ± SEM (n=8–10 animals per group). A significant effect of
time was seen on time to complete the task for all groups (p < 0.05). No sig-
nificant difference between treatment groups or of treatment over time was
observed, Two-Way (time, treatment) Repeated Measures ANOVA.
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DA neurone numbers in this study showed a significant decrease in
both wild type and A30P mice exposed to TCE and TaClo. This finding
is supported by studies that found a similar decrease in DA neurone
number in rats acutely exposed to TCE [8]. A30P overexpression led to
a significant drop in the SNpc DA neurone numbers in the vehicle and
TaClo treated groups, with the effect being more pronounced in the
vehicle group. Although a slight decrease in DA neurone number in the
SNpc of TCE and TaClo treated A30P animals was seen when compared
to wild type, no major additive effect was present. This is consistent
with reports that sensitivity to MPTP is unaltered in A30P mice [22] or
in wild type human α-synuclein overexpressing mice exposed to para-
quat [36]. Density of DA neurones in the SNpc is relatively consistent
with the number of neurones in all groups, which is to be expected as
there was no significant difference in SNpc volume between treatment
groups or strain. Individual DA neuronal volume was measured and
although no treatment effect was seen in cell volume in either strain,
A30P mutant α-synuclein overexpressing animals showed a trend to-
wards larger cell volumes than wild type in vehicle and TCE groups and
were significantly larger in TaClo treated mice.
5. Conclusion
The data observed in this study suggests that TCE and TaClo, can
cause SNpc DA neurone degeneration, but at the doses used, no sig-
nificant acceleration of motor deficits in either wild type or A30P
overexpressing mice. It is possible that the levels of DA cell death in the
SNpc of treated animals are insufficient to cause motor dysfunction
since over 70–80% SNpc cell death is required before behavioural
deficits are seen [1,37]. While TCE and TaClo exposure led to sig-
nificant DA neuronal loss no additive effect of chemical exposure and
A30P overexpression was found. In conclusion, exposure to TCE or
TaClo can cause DA neuronal cell death in the SNpc in vivo, suggesting
TCE exposure as a possible contributory factor in development of PD.
Declaration of Competing Interest
None.
Acknowledgements
The authors would like to thank the staff of the animal care unit for
the care of the animals used in this study. This work was supported by
funding from UK Health Protection Agency (Grant in Aid).
Appendix A. Supplementary data
Supplementary material related to this article can be found, in the
online version, at doi:https://doi.org/10.1016/j.neulet.2019.134437.
References
[1] J.M. Fearnley, A.J. Lees, Ageing and Parkinson’s disease: substantia nigra regional
Fig. 3. Effect of TCE and TaClo on wild type
and A30P α-synuclein overexpressing
C57BL/6 Mouse Spatial Learning Assessed
by the Barnes Maze.
Average (A) primary latency, (B) total latency
(both sec), (C) primary errors and (D) total
errors to find target of vehicle (10ml/kg olive
oil), TCE (100mg/kg) or TaClo (2mg/kg),
treated wild type or A30P α-synuclein over-
expressing C57BL/6 mice over time, quad-
ruplicate trials. Data presented as
mean ± SEM (n=8–10). (A and B)
Significant difference over time (p < 0.001),
No significant difference between treatment
groups or of treatment over time, Two-Way
Repeated Measures ANOVA.
Fig. 4. Effect of TCE and TaClo on SNpc DA
Neuron Number and Density in A30P α-sy-
nuclein overexpressing and wild type
C57BL/6 Mice.
Total (A) number and (B) density of TH-posi-
tive cells in the SNpc of TCE (1000mg/kg),
TaClo (2mg/kg) and vehicle (olive oil) treated
wild type (wt) and A30P overexpressing
C57BL/6 mice wer assessed using a stereo-
logical approach. Analysis of all data and
variables showed a significant overall effect F
(4, 58)= 5.217, p < 0.001, Wilks'
Lambda=0.425 (MANOVA). Post hoc analysis
on the outcome variables revealed a significant
effect on cell density F(5, 29)= 7.361, p < 0.003 and cell number F(5, 29)= 4.236, p=0.043. Data presented as mean± SD (n=5/6). ***p < 0.001, **p < 0.01,
*p < 0.05 when compared to strain vehicle, +p < 0.05 when compared to same treatment wt group (univariate ANOVA). No significant effect was seen on
treatment between strains.
P.C. Keane, et al. Neuroscience Letters 711 (2019) 134437
5
selectivity, Brain 114 (Pt 5) (1991) 2283–2301.
[2] H. Braak, et al., Staging of brain pathology related to sporadic Parkinson’s disease,
Neurobiol. Aging 24 (2) (2003) 197–211.
[3] G.D. Todd, et al., U.D.o.H.a.H. Services (Ed.), Toxicological Profile for
Trichloroethylene, ASTDR, Atlanta, Georgia, USA, 2019, pp. 1–464.
[4] D.M. Gash, et al., Trichloroethylene: Parkinsonism and complex 1 mitochondrial
neurotoxicity, Ann. Neurol. 63 (2) (2008) 184–192.
[5] S.M. Goldman, et al., Solvent exposures and parkinson disease risk in twins, Ann.
Neurol. (2011).
[6] D. Guehl, et al., Trichloroethylene and parkinsonism: a human and experimental
observation, Eur. J. Neurol. 6 (5) (1999) 609–611.
[7] J.S. Reif, et al., Neurobehavioral effects of exposure to trichloroethylene through a
municipal water supply, Environ. Res. 93 (3) (2003) 248–258.
[8] M. Liu, et al., Trichloroethylene induces dopaminergic neurodegeneration in Fisher
344 rats, J. Neurochem. 112 (3) (2011) 773–783.
[9] M. Liu, et al., Trichloroethylene and Parkinson’s disease: risk assessment, Mol.
Neurobiol. 55 (7) (2018) 6201–6214.
[10] G. Bringmann, et al., Identification of the dopaminergic neurotoxin 1-tri-
chloromethyl-1,2, 3,4-tetrahydro-beta-carboline in human blood after intake of the
hypnotic chloral hydrate, Anal. Biochem. 270 (1) (1999) 167–175.
[11] P. Riederer, et al., Biochemical and pharmacological characterization of 1-tri-
chloromethyl-1,2,3,4-tetrahydro-beta-carboline: a biologically relevant neurotoxin?
Eur. J. Pharmacol. 442 (1–2) (2002) 1–16.
[12] W.D. Rausch, et al., Studies of the potentially endogenous toxin TaClo (1-tri-
chloromethyl-1,2,3,4-tetrahydro-beta-carboline) in neuronal and glial cell cultures,
J. Neural Transm. Suppl. 46 (1995) 255–263.
[13] C. Grote, et al., Biochemical lesions of the nigrostriatal system by TaClo (1-tri-
chloromethyl-1,2,3,4-tetrahydro-beta-carboline) and derivatives, J. Neural Transm.
Suppl. 46 (1995) 275–281.
[14] K.H. Sontag, et al., Long-term behavioural effects of TaClo (1-trichloromethyl-
1,2,3,4-tetrahydro-beta-carboline) after subchronic treatment in rats, J. Neural
Transm. Suppl. 46 (1995) 283–289.
[15] C. Heim, K.H. Sontag, The halogenated tetrahydro-beta-carboline “TaClo”: a pro-
gressively-acting neurotoxin, J. Neural Transm. Suppl. 50 (1997) 107–111.
[16] T.A. Sontag, et al., Alterations of nocturnal activity in rats following subchronic oral
administration of the neurotoxin 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carbo-
line, J. Neural Transm. (Vienna) 116 (10) (2009) 1267–1271.
[17] W. Dauer, et al., Resistance of alpha -synuclein null mice to the parkinsonian
neurotoxin MPTP, Proc. Natl. Acad. Sci. U. S. A. 99 (22) (2002) 14524–14529.
[18] M.H. Polymeropoulos, et al., Mutation in the alpha-synuclein gene identified in
families with Parkinson’s disease, Science 276 (5321) (1997) 2045–2047.
[19] R. Kruger, et al., Ala30Pro mutation in the gene encoding alpha-synuclein in
Parkinson’s disease, Nat. Genet. 18 (2) (1998) 106–108.
[20] W. Song, et al., The Parkinson disease-associated A30P mutation stabilizes alpha-
synuclein against proteasomal degradation triggered by heme oxygenase-1 over-
expression in human neuroblastoma cells, J. Neurochem. 110 (2) (2009) 719–733.
[21] P.J. Kahle, et al., Subcellular localization of wild-type and Parkinson’s disease-as-
sociated mutant alpha -synuclein in human and transgenic mouse brain, J.
Neurosci. 20 (17) (2000) 6365–6373.
[22] S. Rathke-Hartlieb, et al., Sensitivity to MPTP is not increased in Parkinson’s dis-
ease-associated mutant alpha-synuclein transgenic mice, J. Neurochem. 77 (4)
(2001) 1181–1184.
[23] P.J. Kahle, et al., Selective insolubility of alpha-synuclein in human Lewy body
diseases is recapitulated in a transgenic mouse model, Am. J. Pathol. 159 (6) (2001)
2215–2225.
[24] B.J. Jones, D.J. Roberts, The quantiative measurement of motor inco-ordination in
naive mice using an acelerating rotarod, J. Pharm. Pharmacol. 20 (4) (1968)
302–304.
[25] P.A. Cabe, et al., A simple recording grip strength device, Pharmacol. Biochem.
Behav. 8 (1) (1978) 101–102.
[26] K. Matsuura, et al., Pole test is a useful method for evaluating the mouse movement
disorder caused by striatal dopamine depletion, J. Neurosci. Methods 73 (1) (1997)
45–48.
[27] C.A. Barnes, Memory deficits associated with senescence: a neurophysiological and
behavioral study in the rat, J. Comp. Physiol. Psychol. 93 (1) (1979) 74–104.
[28] H.J. Gundersen, et al., The new stereological tools: disector, fractionator, nucleator
and point sampled intercepts and their use in pathological research and diagnosis,
APMIS 96 (10) (1988) 857–881.
[29] M.J. West, L. Slomianka, H.J. Gundersen, Unbiased stereological estimation of the
total number of neurons in thesubdivisions of the rat hippocampus using the optical
fractionator, Anat. Rec. 231 (4) (1991) 482–497.
[30] V.A. Colotla, et al., Effects of MPTP on locomotor activity in mice, Neurotoxicol.
Teratol. 12 (4) (1990) 405–407.
[31] C. Freichel, et al., Age-dependent cognitive decline and amygdala pathology in
alpha-synuclein transgenic mice, Neurobiol. Aging 28 (9) (2007) 1421–1435.
[32] S. Ekmark-Lewen, et al., Early fine motor impairment and behavioral dysfunction in
(Thy-1)-h[A30P] alpha-synuclein mice, Brain Behav. 8 (3) (2018) e00915.
[33] M. Sedelis, et al., MPTP susceptibility in the mouse: behavioral, neurochemical, and
histological analysis of gender and strain differences, Behav. Genet. 30 (3) (2000)
171–182.
[34] M. Lawton, et al., Developing and validating Parkinson’s disease subtypes and their
motor and cognitive progression, J. Neurol. Neurosurg. Psychiatry 89 (12) (2018)
1279–1287.
[35] T.A. Sontag, et al., The long-term effects of the neurotoxin 1-trichloromethyl-
1,2,3,4-tetrahydro-beta-carboline (TaClo) on cognitive performance in rats, J.
Neural. Transm. Suppl. 72 (2007) 149–154.
[36] P.O. Fernagut, et al., Behavioral and histopathological consequences of paraquat
intoxication in mice: effects of alpha-synuclein over-expression, Synapse 61 (12)
(2007) 991–1001.
[37] J.L. Tillerson, et al., Detection of behavioral impairments correlated to neuro-
chemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine, Exp. Neurol. 178 (1) (2002) 80–90.
P.C. Keane, et al. Neuroscience Letters 711 (2019) 134437
6
